Requip (ropinirole), the SECOND new drug for Parkinson's to hit the market

    SmithKline Beecham is now marketing Requip (ropinirole), the SECOND new drug for Parkinson's to hit the market this year.

    The first one, Mirapex (pramipexole) was approved in July.

    Requip and Mirapex are second-generation dopamine agonists.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote